BioXcel Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 74
- Market Cap
- $26.8M
- Introduction
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Phase 1
Completed
- Conditions
- DementiaAgitation,Psychomotor
- Interventions
- Drug: Sublingual film containing DexmedetomidineDrug: Sublingual Placebo Film
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 100
- Registration Number
- NCT04251910
- Locations
- 🇺🇸
BioXcel Clinical Research Site, Toms River, New Jersey, United States
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
Early Phase 1
Withdrawn
- Conditions
- Cancer of PancreasCancer of the PancreasNeoplasms, PancreaticPancreas CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- BioXcel Therapeutics Inc
- Registration Number
- NCT04123574
- Locations
- 🇺🇸
BioXcel Clinical Research Site, New York, New York, United States
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
Phase 1
Completed
- Conditions
- SchizophreniaAgitation
- Interventions
- Drug: Placebo filmDrug: Sublingual film containing BXCL501 (Dexmedetomidine)
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 135
- Registration Number
- NCT04010305
- Locations
- 🇺🇸
BioXcel Clinical Research Site, Richardson, Texas, United States
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Phase 1
Active, not recruiting
- Conditions
- Prostate CancerNeuroendocrine TumorsSmall Cell Carcinoma
- Interventions
- Drug: BXCL701 monotherapyDrug: BXCL701 plus Pembrolizumab
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- BioXcel Therapeutics Inc
- Target Recruit Count
- 98
- Registration Number
- NCT03910660
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of California San Francisco (UCSF), San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath